Lupin is currently trading at RS. 1933.30, down by 22.05 points or 1.13% from its previous closing of RS. 1955.35 on the BSE.

The stock opened at RS. 1950.00 and recorded an intraday high of RS. 1957.20 and a low of RS. 1927.65. A total of 10,085 shares have been traded so far on the counter.

Lupin, a BSE group 'A' stock with a face value of RS. 2, hit a 52-week high of RS. 2403.45 on January 2, 2025, and a 52-week low of RS. 1767.20 on July 22, 2024. Over the past week, the stock’s high and low stood at RS. 1961.10 and RS. 1888.05 respectively. The company’s current market capitalization is RS. 88,302.96 crore.

Promoters hold 46.92% of the company’s shares, while Institutions and Non-Institutions hold 46.88% and 6.20% respectively.

The United States Food and Drug Administration (USFDA) has concluded its inspection at Lupin’s Pithampur Unit-2 manufacturing facility. The inspection, conducted from July 8, 2025, to July 17, 2025, ended with the issuance of a Form-483 containing four observations.

Lupin has stated that it is addressing these observations comprehensively and will submit its response to the USFDA within the stipulated timeframe. The company emphasized its commitment to maintaining quality and compliance with CGMP standards across all its facilities.

Lupin is a global, innovation-driven pharmaceutical company engaged in the production, development, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).

Lupin Shares Slip as USFDA Flags Four Observations in Pithampur Unit Inspection

Lupin is trading at RS. 1933.30, down 22.05 points or 1.13% from its previous close of RS. 1955.35 on the BSE.

The stock opened at RS. 1950.00, hitting an intraday high of RS. 1957.20 and a low of RS. 1927.65. So far, 10,085 shares have changed hands on the counter.

This BSE group 'A' stock, with a face value of RS. 2, reached a 52-week high of RS. 2403.45 on January 2, 2025, and a 52-week low of RS. 1767.20 on July 22, 2024. Over the past week, the scrip’s high and low were RS. 1961.10 and RS. 1888.05 respectively. Lupin’s current market capitalization stands at RS. 88,302.96 crore.

The company’s shareholding pattern shows promoters holding 46.92%, institutions at 46.88%, and non-institutions at 6.20%.

Recently, the United States Food and Drug Administration (USFDA) completed its inspection at Lupin’s Pithampur Unit-2 facility. The inspection, conducted from July 8 to July 17, 2025, concluded with the issuance of a Form-483 listing four observations.

Lupin stated it is taking corrective measures and will respond to the USFDA within the specified timeframe. The company reaffirmed its commitment to quality and compliance with CGMP standards across all its facilities.

Lupin remains an innovation-driven global pharmaceutical leader, engaged in developing and marketing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).